Menu
Back to Journals » OncoTargets and Therapy » Volume 9
Original Research
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 11,631 | Dovepress* | 8,849+ | 1,248 | 10,097 | |
| PubMed Central* | 2,782 | 776 | 3,558 | ||
| Totals | 11,631 | 2,024 | 13,655 | ||
| *Since 16 November 2016 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 3 | 0 | 0 | 0 | 1 | 2 |
View citations on PubMed Central and Google Scholar